Literature DB >> 31533941

A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.

Yiwen Zhang1, Cindy Ke Zhou1, Michelangelo Fiorentino2, Ericka M Ebot3, Emily M Rencsok1, Katja Fall1,4, Tamara L Lotan5, Massimo Loda6,7, Francesca Giunchi2, Elizabeth A Platz8,9, Angelo M De Marzo9,10, Lorelei A Mucci1,11.   

Abstract

BACKGROUND: Inflammation and focal atrophy are common features adjacent to prostate tumors. Limited evidence exists on whether these features have prognostic significance.
METHODS: In the Health Professionals Follow-Up Study and Physicians' Health Study, we studied 1,035 men diagnosed with prostate cancer. A genitourinary pathologist centrally reviewed tumor and normal areas of hematoxylin and eosin slides from prostate cancer specimens for the presence of acute and chronic inflammation, and four subtypes of focal atrophy. Cox proportional hazards models adjusted for potential confounders were used to estimate HRs and 95% confidence intervals (CI) for the association of these features with lethal prostate cancer, defined as development of metastatic disease or death during follow-up.
RESULTS: During a median of 12 years of follow-up, 153 men developed lethal prostate cancer. A total of 84% of men had histologic evidence of chronic inflammation and 30% had acute inflammation. Both chronic and acute inflammation were inversely associated with lethal prostate cancer in age- and lifestyle-adjusted models. Chronic inflammation remained inversely associated with lethal prostate cancer after additionally adjusting for prognostic clinical features (HR = 0.45; 95% CI, 0.30-0.69 for mild and HR = 0.51; 95% CI, 0.33-0.80 for moderate to severe). None of the atrophic lesions were associated with lethal prostate cancer.
CONCLUSIONS: Our data suggest that the presence of inflammation, particularly chronic inflammation, in prostate cancer tissue is associated with better prognosis among patients with prostate cancer. IMPACT: This is the largest prospective cohort study to examine the association between inflammation, focal atrophy, and lethal prostate cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31533941      PMCID: PMC6941930          DOI: 10.1158/1055-9965.EPI-19-0713

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

1.  Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.

Authors:  Edward Giovannucci; Yan Liu; Elizabeth A Platz; Meir J Stampfer; Walter C Willett
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

2.  Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study.

Authors:  Elizabeth A Platz; Charles G Drake; Kathryn M Wilson; Siobhan Sutcliffe; Stacey A Kenfield; Lorelei A Mucci; Meir J Stampfer; Walter C Willett; Carlos A Camargo; Edward Giovannucci
Journal:  Int J Cancer       Date:  2015-02-27       Impact factor: 7.396

3.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 4.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

5.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

6.  Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.

Authors:  Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Emanuela Taioli; Jay H Fowke; Stephen J Freedland
Journal:  Cancer Causes Control       Date:  2018-04-17       Impact factor: 2.506

7.  High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group.

Authors:  J Irani; J M Goujon; E Ragni; L Peyrat; J Hubert; F Saint; N Mottet
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

8.  Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

Authors:  Daniel M Moreira; David G Bostwick; Gerald L Andriole; Bercedis L Peterson; Harvey J Cohen; Ramiro Castro-Santamaria; Stephen J Freedland
Journal:  J Urol       Date:  2015-07-10       Impact factor: 7.450

9.  A working group classification of focal prostate atrophy lesions.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Jonathan I Epstein; Tehmina Ali; Anthanase Billis; Teresa Y Chan; Liang Cheng; Milton Datta; Lars Egevad; Dilek Ertoy-Baydar; Xavier Farre; Xavier Farree; Samson W Fine; Kenneth A Iczkowski; Michael Ittmann; Beatrice S Knudsen; Massimo Loda; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Gregor Mikuz; Roldolfo Montironi; Eli Pikarsky; Galina Pizov; Mark A Rubin; Hema Samaratunga; Thomas Sebo; Isabel A Sesterhenn; Rajal B Shah; Rajiv B Shah; Sabina Signoretti; Jeffery Simko; George Thomas; Patricia Troncoso; Toyonori T Tsuzuki; Geert J van Leenders; Ximing J Yang; Ming Zhou; William D Figg; Ashraful Hoque; Ashrafal Hoque; M S Lucia
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

Review 10.  The role of inflammation in prostate cancer.

Authors:  Karen S Sfanos; Heidi A Hempel; Angelo M De Marzo
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

View more
  4 in total

1.  Why Do Epidemiologic Studies Find an Inverse Association Between Intraprostatic Inflammation and Prostate Cancer: A Possible Role for Colliding Bias?

Authors:  Marvin E Langston; Karen S Sfanos; Saira Khan; Trang Q Nguyen; Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02       Impact factor: 4.090

2.  Characterization of fecal microbiome in biopsy positive prostate cancer patients.

Authors:  Ran Katz; Muhamad Abu Ahmed; Ali Safadi; Wasiem Abu Nasra; Alexander Visoki; Michael Huckim; Ibrahim Elias; Meital Nuriel-Ohayon; Hadar Neuman
Journal:  BJUI Compass       Date:  2021-09-07

3.  Urinary microbiome profile in men with genitourinary malignancies.

Authors:  Hyun Kyu Ahn; Kwangmin Kim; Junhyung Park; Kwang Hyun Kim
Journal:  Investig Clin Urol       Date:  2022-09

Review 4.  Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention.

Authors:  Lanshan Huang; Melissa J LaBonte; Stephanie G Craig; Stephen P Finn; Emma H Allott
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.